143 related articles for article (PubMed ID: 10093301)
1. Chlamydia pneumoniae antibodies associated with altered serum lipid profile.
Laurila AL; Bloigu A; Näyhä S; Hassi J; Leinonen M; Saikku P
Int J Circumpolar Health; 1998; 57 Suppl 1():329-32. PubMed ID: 10093301
[TBL] [Abstract][Full Text] [Related]
2. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis.
Laurila A; Bloigu A; Näyhä S; Hassi J; Leinonen M; Saikku P
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2910-3. PubMed ID: 9409275
[TBL] [Abstract][Full Text] [Related]
3. [Detection of serum Chlamydia pneumoniae antibodies and analysis of epidemiologic data in 5 years].
Cui J; Yan W; Ni A; Kong L; Chen L
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):919-23. PubMed ID: 24854912
[TBL] [Abstract][Full Text] [Related]
4. [Chlamydia pneumoniae in patients with atherosclerotic ischemia of the lower limbs].
Drozdz W; Zawilińska B; Wysocki A; Kleszcz E; Wilczek M
Przegl Lek; 2003; 60 Suppl 7():53-5. PubMed ID: 14679694
[TBL] [Abstract][Full Text] [Related]
5. Serological evidence of Chlamydia pneumoniae lipopolysaccharide antibodies in atherosclerosis of various vascular regions.
Körner I; Blatz R; Wittig I; Pfeiffer D; Rühlmann C
Vasa; 1999 Nov; 28(4):259-63. PubMed ID: 10611843
[TBL] [Abstract][Full Text] [Related]
6. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile.
Hoffmeister A; Rothenbacher D; Bode G; Persson K; März W; Nauck MA; Brenner H; Hombach V; Koenig W
Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):427-32. PubMed ID: 11231924
[TBL] [Abstract][Full Text] [Related]
7. Changes in antibody titers against Chlamydia pneumoniae after coronary angioplasty.
Yetkin G; Yetkin E; Aksoy Y; Gurbuz OA; Mert A
Int J Cardiol; 2004 Jun; 95(2-3):293-7. PubMed ID: 15193835
[TBL] [Abstract][Full Text] [Related]
8. [Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease].
Duan Z; Liu S; Wang B
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Apr; 24(4):208-11. PubMed ID: 11802964
[TBL] [Abstract][Full Text] [Related]
9. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis.
Leinonen M; Saikku P
Am Heart J; 1999 Nov; 138(5 Pt 2):S504-6. PubMed ID: 10539859
[TBL] [Abstract][Full Text] [Related]
10. [Chlamydia pneumoniae and atherosclerosis].
Andreasen JJ
Ugeskr Laeger; 1997 Sep; 159(37):5503-7. PubMed ID: 9312918
[TBL] [Abstract][Full Text] [Related]
11. The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies.
Glader CA; Boman J; Saikku P; Stenlund H; Weinehall L; Hallmanns G; Dahlén GH
Eur Heart J; 2000 Apr; 21(8):639-46. PubMed ID: 10731401
[TBL] [Abstract][Full Text] [Related]
12. Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile.
Murray LJ; O'Reilly DP; Ong GM; O'Neill C; Evans AE; Bamford KB
Heart; 1999 Mar; 81(3):239-44. PubMed ID: 10026343
[TBL] [Abstract][Full Text] [Related]
13. Association of Helicobacter pylori infection with elevated serum lipids.
Laurila A; Bloigu A; Näyhä S; Hassi J; Leinonen M; Saikku P
Atherosclerosis; 1999 Jan; 142(1):207-10. PubMed ID: 9920523
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of Chlamydophila pneumoniae in ischaemic heart disease.
Monno R; Fumarola L; Trerotoli P; Giannelli G; Correale M; Brunetti D; Di Biase M
New Microbiol; 2010 Oct; 33(4):381-5. PubMed ID: 21213597
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of human monocyte-macrophages to Chlamydia pneumoniae infection in vitro is highly variable and associated with levels of soluble CD14 and C. pneumoniae IgA and human HSP-IgG antibodies in serum.
Poikonen K; Lajunen T; Silvennoinen-Kassinen S; Paldanius M; Leinonen M; Saikku P
Scand J Immunol; 2008 Mar; 67(3):279-84. PubMed ID: 18194359
[TBL] [Abstract][Full Text] [Related]
16. Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases.
Romano Carratelli C; Nuzzo I; Cozzolino D; Bentivoglio C; Paolillo R; Rizzo A
Int Immunopharmacol; 2006 May; 6(5):848-53. PubMed ID: 16546716
[TBL] [Abstract][Full Text] [Related]
17. The progression of lower limb atherosclerosis is associated with IgA antibodies against Chlamydia pneumoniae.
Lindholt JS; Vammen S; Lind I; Fasting H; Henneberg EW
Eur J Vasc Endovasc Surg; 1999 Dec; 18(6):527-9. PubMed ID: 10637151
[TBL] [Abstract][Full Text] [Related]
18. [Part of Chlamydia pneumoniae in atherosclerosis and exacerbation of chronic obstructive pulmonary disease and asthma].
Azzouzi N; Elhataoui M; Bakhatar A; Takourt B; Benslimane A
Ann Biol Clin (Paris); 2005; 63(2):179-84. PubMed ID: 15771975
[TBL] [Abstract][Full Text] [Related]
19. [Presence of Chlamydia pneumoniae antibodies in patients with ischemic heart disease and acute myocardial infarct].
Reiner Z; Burek V; Goldner V; Jug M; Zrnić T; Oresković K; Culig J
Lijec Vjesn; 2000; 122(11-12):263-9. PubMed ID: 11291268
[TBL] [Abstract][Full Text] [Related]
20. [Investigation of Chlamydophila pneumoniae seropositivity and risk factors in patients with atherosclerotic vascular disease in Sivas, Turkey].
Kılıç ZB; Poyraz O; Kılıç AT
Mikrobiyol Bul; 2012 Jan; 46(1):156-8. PubMed ID: 22399186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
